The abrupt exit of the former CBER director, who quickly made his mark at the agency with several high-profile and controversial decisions, raises questions about where the FDA is headed.
The abrupt exit of the former CBER director, who quickly made his mark at the agency with several high-profile and controversial decisions, raises questions about where the FDA is headed.
